Does cabozantinib have an effect on phosphocarcinoma?

Cabozantinib, as a broad-spectrum anticancer drug, has shown remarkable effects in the treatment of various cancers in recent years. Cabozantinib has also shown some therapeutic effect against phosphocarcinoma, that is, squamous cell carcinoma.

Cabozantinib exerts anti-cancer effects by inhibiting multiple receptor tyrosine kinases, such as MET, VEGFR, AXL, etc. These kinases play key roles in tumor growth, metastasis, and angiogenesis. Cabozantinib can inhibit the activity of these kinases at the same time, thereby blocking the signal transduction of tumor cells and inhibiting the growth and spread of tumors.

In clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), cabozantinib combined with pembrolizumab (an immunotherapy drug) has achieved remarkable results. This combination treatment not only improved the patient's objective response rate (ORR), but also prolonged the patient's progression-free survival (PFS) and overall survival (OS). Specifically, in a II phase clinical trial, the ORR of patients who received the combination therapy reached 54%, and the clinical benefit rate was as high as 91%. Additionally, patients' median PFS was 14.6 months, with a PFS rate of 1 year and a PFS rate of 54%; The median OS was 22.3 months, and the 1 year OS rate was 68.4%. These data fully demonstrate the effectiveness of cabozantinib in the treatment of squamous cell carcinoma.

Although cabozantinib has shown significant efficacy in the treatment of squamous cell carcinoma, its safety is also an important factor to consider. Clinical trial data show that the adverse reactions of cabozantinib mainly include fatigue, hypertension, diarrhea, weight loss, etc. However, most of these adverse effects can be alleviated with appropriate medication adjustments and supportive care. Overall, patients tolerated cabozantinib well.